| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 23 | 2020 | 691 | 3.300 |
Why?
|
| Intracranial Aneurysm | 12 | 2020 | 68 | 3.090 |
Why?
|
| Thrombectomy | 11 | 2020 | 74 | 2.380 |
Why?
|
| Brain Ischemia | 12 | 2020 | 159 | 1.910 |
Why?
|
| Aneurysm, Ruptured | 5 | 2016 | 33 | 1.670 |
Why?
|
| Humans | 137 | 2021 | 32274 | 1.490 |
Why?
|
| Cerebral Angiography | 8 | 2020 | 60 | 1.450 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2021 | 907 | 1.330 |
Why?
|
| Middle Aged | 65 | 2020 | 11848 | 1.240 |
Why?
|
| Female | 79 | 2021 | 19942 | 1.100 |
Why?
|
| Male | 77 | 2020 | 19437 | 1.080 |
Why?
|
| Mandible | 7 | 2018 | 39 | 1.060 |
Why?
|
| Intracranial Hemorrhages | 4 | 2017 | 34 | 1.050 |
Why?
|
| Aged | 47 | 2020 | 10260 | 0.970 |
Why?
|
| Arteriovenous Fistula | 3 | 2016 | 19 | 0.970 |
Why?
|
| Embolization, Therapeutic | 6 | 2020 | 81 | 0.960 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2016 | 19 | 0.920 |
Why?
|
| Neurosurgery | 3 | 2016 | 36 | 0.920 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 489 | 0.910 |
Why?
|
| Retrospective Studies | 31 | 2020 | 3624 | 0.910 |
Why?
|
| Adult | 45 | 2021 | 9256 | 0.830 |
Why?
|
| Mouth Neoplasms | 7 | 2019 | 17 | 0.740 |
Why?
|
| Dental Implants | 4 | 2013 | 7 | 0.740 |
Why?
|
| Aged, 80 and over | 25 | 2020 | 3898 | 0.730 |
Why?
|
| Stents | 10 | 2020 | 159 | 0.730 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2019 | 38 | 0.720 |
Why?
|
| Cerebrovascular Circulation | 3 | 2019 | 93 | 0.720 |
Why?
|
| Renal Dialysis | 3 | 2019 | 276 | 0.690 |
Why?
|
| Carotid Artery, Internal | 2 | 2019 | 33 | 0.690 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 595 | 0.670 |
Why?
|
| Edetic Acid | 1 | 2020 | 9 | 0.650 |
Why?
|
| Models, Anatomic | 2 | 2020 | 37 | 0.650 |
Why?
|
| Bone Diseases | 1 | 2020 | 15 | 0.650 |
Why?
|
| Corneal Transplantation | 1 | 2020 | 14 | 0.640 |
Why?
|
| Oligopeptides | 1 | 2020 | 49 | 0.640 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 2240 | 0.630 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 6 | 0.620 |
Why?
|
| Ribs | 1 | 2020 | 44 | 0.620 |
Why?
|
| Periodicals as Topic | 3 | 2015 | 91 | 0.610 |
Why?
|
| Treatment Outcome | 26 | 2020 | 3416 | 0.610 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 51 | 0.610 |
Why?
|
| Artifacts | 1 | 2019 | 45 | 0.610 |
Why?
|
| Urology | 1 | 2019 | 33 | 0.600 |
Why?
|
| Superior Sagittal Sinus | 1 | 2019 | 5 | 0.590 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2019 | 7 | 0.590 |
Why?
|
| Sex Characteristics | 2 | 2018 | 173 | 0.590 |
Why?
|
| Models, Biological | 4 | 2016 | 408 | 0.580 |
Why?
|
| Urologic Surgical Procedures | 1 | 2019 | 66 | 0.580 |
Why?
|
| Adolescent | 18 | 2020 | 3517 | 0.580 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 116 | 0.580 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 44 | 0.580 |
Why?
|
| Bone Transplantation | 3 | 2013 | 51 | 0.560 |
Why?
|
| Intestines | 3 | 2019 | 63 | 0.560 |
Why?
|
| Middle Cerebral Artery | 1 | 2018 | 13 | 0.550 |
Why?
|
| Fluoresceins | 1 | 2017 | 9 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 3 | 2019 | 534 | 0.530 |
Why?
|
| Glucuronidase | 1 | 2017 | 12 | 0.520 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 52 | 0.510 |
Why?
|
| Bacteria | 1 | 2017 | 54 | 0.500 |
Why?
|
| Physicians | 2 | 2020 | 163 | 0.500 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 98 | 0.500 |
Why?
|
| Health Status Disparities | 1 | 2018 | 128 | 0.500 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 35 | 0.500 |
Why?
|
| Zinc | 1 | 2016 | 29 | 0.500 |
Why?
|
| Young Adult | 15 | 2020 | 2648 | 0.490 |
Why?
|
| Troponin T | 1 | 2017 | 91 | 0.490 |
Why?
|
| Tibia | 2 | 2013 | 56 | 0.480 |
Why?
|
| Temporomandibular Joint | 2 | 2015 | 2 | 0.480 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 264 | 0.480 |
Why?
|
| Catheter Ablation | 5 | 2013 | 113 | 0.460 |
Why?
|
| Maxilla | 3 | 2017 | 10 | 0.460 |
Why?
|
| Informed Consent | 1 | 2015 | 44 | 0.440 |
Why?
|
| Self-Help Groups | 1 | 2014 | 11 | 0.440 |
Why?
|
| Hippocratic Oath | 1 | 2014 | 1 | 0.430 |
Why?
|
| Finite Element Analysis | 3 | 2015 | 85 | 0.420 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 16 | 0.420 |
Why?
|
| Heart Failure | 5 | 2020 | 728 | 0.410 |
Why?
|
| Animals | 25 | 2019 | 8199 | 0.410 |
Why?
|
| Fractures, Bone | 2 | 2012 | 142 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 157 | 0.400 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 21 | 0.400 |
Why?
|
| Neurosurgical Procedures | 3 | 2020 | 94 | 0.400 |
Why?
|
| Kidney Neoplasms | 4 | 2013 | 200 | 0.390 |
Why?
|
| Imaging, Three-Dimensional | 8 | 2017 | 132 | 0.380 |
Why?
|
| Menopause, Premature | 1 | 2012 | 11 | 0.370 |
Why?
|
| Trismus | 1 | 2012 | 4 | 0.370 |
Why?
|
| Adnexal Diseases | 1 | 2012 | 5 | 0.370 |
Why?
|
| Apoptosis | 7 | 2020 | 375 | 0.350 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 89 | 0.350 |
Why?
|
| Radiology | 3 | 2010 | 34 | 0.350 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 883 | 0.350 |
Why?
|
| Checklist | 1 | 2011 | 39 | 0.350 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 55 | 0.340 |
Why?
|
| Thrombolytic Therapy | 4 | 2018 | 63 | 0.340 |
Why?
|
| Circle of Willis | 1 | 2011 | 2 | 0.340 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 9 | 0.330 |
Why?
|
| Prospective Studies | 9 | 2020 | 2316 | 0.330 |
Why?
|
| Medical Informatics | 1 | 2011 | 26 | 0.330 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2016 | 73 | 0.330 |
Why?
|
| Schools, Medical | 1 | 2011 | 43 | 0.330 |
Why?
|
| Dental Prosthesis Design | 2 | 2013 | 3 | 0.330 |
Why?
|
| Computer-Aided Design | 1 | 2010 | 5 | 0.320 |
Why?
|
| Device Removal | 1 | 2010 | 39 | 0.320 |
Why?
|
| Prognathism | 3 | 2018 | 4 | 0.310 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 150 | 0.310 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 216 | 0.300 |
Why?
|
| Nanoparticles | 3 | 2019 | 52 | 0.300 |
Why?
|
| Osteotomy | 3 | 2018 | 55 | 0.300 |
Why?
|
| Interleukin-6 | 3 | 2017 | 224 | 0.290 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 112 | 0.290 |
Why?
|
| Drug Carriers | 2 | 2019 | 22 | 0.290 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2019 | 897 | 0.290 |
Why?
|
| Mice | 13 | 2019 | 2571 | 0.280 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 215 | 0.280 |
Why?
|
| United States | 11 | 2020 | 4072 | 0.280 |
Why?
|
| Educational Status | 2 | 2020 | 167 | 0.280 |
Why?
|
| Face | 2 | 2018 | 29 | 0.270 |
Why?
|
| Kidney | 4 | 2017 | 521 | 0.270 |
Why?
|
| Myocardium | 3 | 2017 | 184 | 0.270 |
Why?
|
| Rats | 9 | 2019 | 1895 | 0.260 |
Why?
|
| Aneurysm | 2 | 2019 | 20 | 0.260 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 93 | 0.260 |
Why?
|
| Patient Selection | 2 | 2015 | 272 | 0.250 |
Why?
|
| Cell Proliferation | 6 | 2020 | 603 | 0.250 |
Why?
|
| Child | 9 | 2015 | 2434 | 0.250 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2017 | 56 | 0.240 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2004 | 88 | 0.240 |
Why?
|
| Bone and Bones | 4 | 2018 | 91 | 0.240 |
Why?
|
| Radiography | 6 | 2017 | 362 | 0.240 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2004 | 113 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 316 | 0.230 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 59 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2015 | 37 | 0.230 |
Why?
|
| Crowns | 1 | 2005 | 1 | 0.230 |
Why?
|
| Time Factors | 8 | 2019 | 2204 | 0.230 |
Why?
|
| Dental Prosthesis, Implant-Supported | 1 | 2005 | 2 | 0.230 |
Why?
|
| Nanostructures | 1 | 2005 | 20 | 0.230 |
Why?
|
| Morbidity | 2 | 2016 | 98 | 0.230 |
Why?
|
| Case-Control Studies | 5 | 2016 | 854 | 0.230 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 52 | 0.230 |
Why?
|
| Adenoviridae | 1 | 2005 | 68 | 0.220 |
Why?
|
| Mice, Nude | 5 | 2018 | 285 | 0.220 |
Why?
|
| Genetic Vectors | 1 | 2005 | 108 | 0.220 |
Why?
|
| Risk Factors | 6 | 2017 | 3934 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 423 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2018 | 46 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 729 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Liver Neoplasms | 2 | 2002 | 164 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 757 | 0.200 |
Why?
|
| Facial Injuries | 2 | 2015 | 11 | 0.200 |
Why?
|
| Internationality | 1 | 2003 | 22 | 0.200 |
Why?
|
| Bone Density | 5 | 2012 | 169 | 0.200 |
Why?
|
| Neuroprotective Agents | 3 | 2012 | 32 | 0.200 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 312 | 0.200 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2013 | 17 | 0.200 |
Why?
|
| Temporal Bone | 2 | 2013 | 19 | 0.200 |
Why?
|
| Aorta, Thoracic | 1 | 2004 | 81 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Myxoma | 1 | 2003 | 5 | 0.200 |
Why?
|
| Maxillary Sinus | 3 | 2012 | 5 | 0.200 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 19 | 0.190 |
Why?
|
| Publishing | 1 | 2003 | 66 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2020 | 1840 | 0.190 |
Why?
|
| Mitral Valve | 1 | 2003 | 33 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2003 | 58 | 0.190 |
Why?
|
| Child, Preschool | 7 | 2013 | 1233 | 0.190 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 174 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 38 | 0.190 |
Why?
|
| Automation | 2 | 2019 | 28 | 0.190 |
Why?
|
| Prognosis | 3 | 2016 | 1534 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2002 | 34 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 395 | 0.180 |
Why?
|
| Age Factors | 4 | 2018 | 1179 | 0.180 |
Why?
|
| Stroke Volume | 3 | 2020 | 417 | 0.180 |
Why?
|
| Lung | 3 | 2021 | 263 | 0.170 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2013 | 25 | 0.170 |
Why?
|
| Taiwan | 3 | 2019 | 11 | 0.170 |
Why?
|
| Infant | 5 | 2013 | 1010 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2018 | 13 | 0.170 |
Why?
|
| Radiology Information Systems | 2 | 2012 | 12 | 0.170 |
Why?
|
| Software | 2 | 2019 | 124 | 0.160 |
Why?
|
| Limit of Detection | 2 | 2017 | 12 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2021 | 50 | 0.160 |
Why?
|
| Keratoconus | 1 | 2020 | 2 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 74 | 0.160 |
Why?
|
| Pseudophakia | 1 | 2020 | 3 | 0.160 |
Why?
|
| Kenya | 1 | 2020 | 21 | 0.160 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2020 | 2 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 324 | 0.160 |
Why?
|
| Privacy | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 10 | 0.160 |
Why?
|
| Sarcoma, Synovial | 1 | 2020 | 6 | 0.160 |
Why?
|
| Health Records, Personal | 1 | 2020 | 11 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 10 | 0.160 |
Why?
|
| X-Ray Microtomography | 4 | 2013 | 45 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 39 | 0.160 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2020 | 2 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 541 | 0.160 |
Why?
|
| Brain | 4 | 2009 | 965 | 0.160 |
Why?
|
| Radial Artery | 1 | 2020 | 16 | 0.160 |
Why?
|
| Fear | 1 | 2020 | 42 | 0.160 |
Why?
|
| Employment | 1 | 2020 | 44 | 0.160 |
Why?
|
| Cardiac Output, High | 1 | 2019 | 2 | 0.160 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 27 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 46 | 0.160 |
Why?
|
| Metformin | 1 | 2019 | 25 | 0.150 |
Why?
|
| Choroid | 1 | 2019 | 4 | 0.150 |
Why?
|
| Foreign-Body Migration | 1 | 2019 | 10 | 0.150 |
Why?
|
| Sympathectomy | 1 | 2019 | 23 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 4 | 2017 | 302 | 0.150 |
Why?
|
| Sympathetic Nervous System | 1 | 2019 | 34 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 55 | 0.150 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 46 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2014 | 144 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 90 | 0.150 |
Why?
|
| Venous Thrombosis | 3 | 2006 | 43 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2019 | 68 | 0.150 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 14 | 0.150 |
Why?
|
| Arecoline | 1 | 2019 | 3 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2013 | 251 | 0.150 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2016 | 18 | 0.150 |
Why?
|
| Orthognathic Surgical Procedures | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hospices | 1 | 2018 | 5 | 0.150 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2019 | 82 | 0.150 |
Why?
|
| Phosphatidylethanolamines | 1 | 2018 | 8 | 0.140 |
Why?
|
| Antibodies, Bispecific | 1 | 2018 | 5 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 5 | 0.140 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2018 | 10 | 0.140 |
Why?
|
| Health Behavior | 1 | 2020 | 211 | 0.140 |
Why?
|
| Protein Multimerization | 1 | 2018 | 25 | 0.140 |
Why?
|
| Sciatica | 2 | 2016 | 3 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 34 | 0.140 |
Why?
|
| Incidence | 3 | 2017 | 1241 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 71 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 56 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 63 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2019 | 153 | 0.140 |
Why?
|
| Embolectomy | 2 | 2015 | 6 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 98 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 95 | 0.140 |
Why?
|
| Taxoids | 1 | 2018 | 50 | 0.140 |
Why?
|
| Cheek | 1 | 2018 | 6 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 43 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 131 | 0.140 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 63 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 120 | 0.140 |
Why?
|
| Adiponectin | 1 | 2018 | 94 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 264 | 0.140 |
Why?
|
| Cephalometry | 4 | 2018 | 17 | 0.140 |
Why?
|
| Body Weight | 1 | 2019 | 323 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 1223 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 84 | 0.140 |
Why?
|
| Microfluidics | 2 | 2017 | 18 | 0.140 |
Why?
|
| Quebec | 1 | 2017 | 3 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2015 | 153 | 0.130 |
Why?
|
| Heart Injuries | 1 | 2017 | 9 | 0.130 |
Why?
|
| Stress, Mechanical | 4 | 2015 | 96 | 0.130 |
Why?
|
| Decision Making | 1 | 2019 | 189 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2020 | 178 | 0.130 |
Why?
|
| Hydrolysis | 1 | 2017 | 41 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 502 | 0.130 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 15 | 0.130 |
Why?
|
| Mandibular Advancement | 1 | 2017 | 2 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 18 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2019 | 484 | 0.130 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 60 | 0.130 |
Why?
|
| Angioplasty | 3 | 2020 | 29 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 76 | 0.130 |
Why?
|
| Escherichia coli | 1 | 2017 | 88 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2013 | 21 | 0.130 |
Why?
|
| HIV Infections | 2 | 2014 | 450 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 212 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 232 | 0.120 |
Why?
|
| Endocarditis, Subacute Bacterial | 1 | 2016 | 1 | 0.120 |
Why?
|
| Pyomyositis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Staphylococcus haemolyticus | 1 | 2016 | 2 | 0.120 |
Why?
|
| Phenothiazines | 1 | 2016 | 1 | 0.120 |
Why?
|
| Buttocks | 1 | 2016 | 5 | 0.120 |
Why?
|
| Neurologic Examination | 1 | 2016 | 30 | 0.120 |
Why?
|
| African Americans | 2 | 2020 | 1335 | 0.120 |
Why?
|
| Dental Prosthesis Retention | 2 | 2013 | 3 | 0.120 |
Why?
|
| Dental Implantation, Endosseous | 2 | 2013 | 4 | 0.120 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 20 | 0.120 |
Why?
|
| Logistic Models | 3 | 2018 | 743 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 30 | 0.120 |
Why?
|
| Bumetanide | 1 | 2016 | 2 | 0.120 |
Why?
|
| Natriuresis | 1 | 2016 | 5 | 0.120 |
Why?
|
| Mandibular Nerve | 1 | 2015 | 1 | 0.120 |
Why?
|
| Tooth, Impacted | 1 | 2015 | 1 | 0.120 |
Why?
|
| Molar, Third | 1 | 2015 | 2 | 0.120 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 11 | 0.120 |
Why?
|
| Regeneration | 1 | 2017 | 178 | 0.120 |
Why?
|
| Antioxidants | 1 | 2016 | 122 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 381 | 0.120 |
Why?
|
| Subdural Effusion | 1 | 2015 | 4 | 0.120 |
Why?
|
| Bicycling | 1 | 2015 | 12 | 0.120 |
Why?
|
| Sodium | 1 | 2016 | 41 | 0.120 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2015 | 5 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 30 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 79 | 0.110 |
Why?
|
| Mandibular Prosthesis | 1 | 2015 | 2 | 0.110 |
Why?
|
| Mandibular Condyle | 1 | 2015 | 5 | 0.110 |
Why?
|
| Phenylcarbamates | 2 | 2005 | 3 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 245 | 0.110 |
Why?
|
| Writing | 1 | 2015 | 12 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 717 | 0.110 |
Why?
|
| Research Personnel | 1 | 2015 | 22 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 465 | 0.110 |
Why?
|
| Catheterization | 3 | 2020 | 55 | 0.110 |
Why?
|
| Coal Mining | 1 | 2014 | 1 | 0.110 |
Why?
|
| Contrast Media | 2 | 2013 | 136 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2014 | 25 | 0.110 |
Why?
|
| Posterior Cerebral Artery | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 43 | 0.110 |
Why?
|
| Particulate Matter | 1 | 2014 | 32 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2009 | 319 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 368 | 0.110 |
Why?
|
| HIV-1 | 2 | 2014 | 46 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2017 | 727 | 0.110 |
Why?
|
| Registries | 1 | 2015 | 294 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 506 | 0.100 |
Why?
|
| Magnetics | 1 | 2014 | 5 | 0.100 |
Why?
|
| Ferrous Compounds | 1 | 2014 | 6 | 0.100 |
Why?
|
| Ammonia | 1 | 2014 | 8 | 0.100 |
Why?
|
| Equipment Failure Analysis | 2 | 2013 | 44 | 0.100 |
Why?
|
| Psychometrics | 1 | 2014 | 137 | 0.100 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 853 | 0.100 |
Why?
|
| Pteridines | 1 | 2013 | 1 | 0.100 |
Why?
|
| Ear, Inner | 1 | 2013 | 8 | 0.100 |
Why?
|
| Dentistry | 1 | 2013 | 4 | 0.100 |
Why?
|
| Chicago | 1 | 2013 | 10 | 0.100 |
Why?
|
| Surface Properties | 2 | 2012 | 37 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2013 | 22 | 0.100 |
Why?
|
| False Positive Reactions | 1 | 2013 | 27 | 0.100 |
Why?
|
| Biomimetic Materials | 1 | 2013 | 15 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 58 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 44 | 0.100 |
Why?
|
| Curcumin | 1 | 2013 | 8 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 8 | 0.100 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2013 | 35 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 86 | 0.100 |
Why?
|
| Ear | 1 | 2013 | 15 | 0.100 |
Why?
|
| Insulin | 2 | 2013 | 359 | 0.100 |
Why?
|
| Dental Stress Analysis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Zirconium | 1 | 2013 | 2 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2019 | 239 | 0.100 |
Why?
|
| Medical Records | 2 | 2010 | 75 | 0.100 |
Why?
|
| Titanium | 1 | 2013 | 10 | 0.100 |
Why?
|
| Shear Strength | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cell Survival | 4 | 2016 | 288 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 106 | 0.090 |
Why?
|
| Bufanolides | 1 | 2012 | 1 | 0.090 |
Why?
|
| Catechin | 1 | 2012 | 4 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 181 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 2 | 2018 | 72 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 35 | 0.090 |
Why?
|
| Postoperative Complications | 4 | 2013 | 823 | 0.090 |
Why?
|
| Hospitalization | 1 | 2015 | 475 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2014 | 461 | 0.090 |
Why?
|
| Femur | 1 | 2012 | 75 | 0.090 |
Why?
|
| Patient Access to Records | 1 | 2012 | 4 | 0.090 |
Why?
|
| Mesenteric Vascular Occlusion | 2 | 2002 | 12 | 0.090 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2012 | 2 | 0.090 |
Why?
|
| Copper | 1 | 2012 | 11 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2012 | 56 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 444 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 74 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 137 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 520 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 21 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2013 | 553 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 48 | 0.090 |
Why?
|
| Alzheimer Disease | 2 | 2005 | 280 | 0.090 |
Why?
|
| Ductus Arteriosus | 1 | 2011 | 2 | 0.090 |
Why?
|
| Heart Aneurysm | 1 | 2011 | 3 | 0.090 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2017 | 101 | 0.090 |
Why?
|
| Reactive Oxygen Species | 4 | 2016 | 163 | 0.090 |
Why?
|
| Structure-Activity Relationship | 2 | 2016 | 87 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 75 | 0.090 |
Why?
|
| Protein Binding | 3 | 2018 | 244 | 0.090 |
Why?
|
| Fetal Diseases | 1 | 2011 | 17 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2011 | 8 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 33 | 0.090 |
Why?
|
| Morpholines | 2 | 2009 | 47 | 0.090 |
Why?
|
| Pia Mater | 1 | 2011 | 2 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 89 | 0.080 |
Why?
|
| Facial Bones | 1 | 2011 | 8 | 0.080 |
Why?
|
| Collateral Circulation | 1 | 2011 | 10 | 0.080 |
Why?
|
| Skull Fractures | 1 | 2011 | 16 | 0.080 |
Why?
|
| Range of Motion, Articular | 1 | 2012 | 196 | 0.080 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2011 | 15 | 0.080 |
Why?
|
| Angiography | 2 | 2020 | 76 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2013 | 414 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 49 | 0.080 |
Why?
|
| Hippocampus | 1 | 2012 | 216 | 0.080 |
Why?
|
| Fibrinolytic Agents | 3 | 2017 | 63 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 202 | 0.080 |
Why?
|
| Assisted Circulation | 1 | 2010 | 1 | 0.080 |
Why?
|
| Acupuncture Analgesia | 1 | 2010 | 1 | 0.080 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 15 | 0.080 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2010 | 11 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 231 | 0.080 |
Why?
|
| Hardness | 1 | 2010 | 5 | 0.080 |
Why?
|
| Elastic Modulus | 1 | 2010 | 29 | 0.080 |
Why?
|
| Afferent Pathways | 1 | 2010 | 40 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 287 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 754 | 0.080 |
Why?
|
| Conscious Sedation | 1 | 2010 | 24 | 0.080 |
Why?
|
| Adenosine | 1 | 2010 | 68 | 0.080 |
Why?
|
| Anesthesia, General | 1 | 2010 | 30 | 0.080 |
Why?
|
| Prosthesis Design | 1 | 2010 | 106 | 0.080 |
Why?
|
| Molar | 2 | 2009 | 4 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2010 | 51 | 0.080 |
Why?
|
| Dentigerous Cyst | 1 | 2009 | 1 | 0.080 |
Why?
|
| Radicular Cyst | 1 | 2009 | 1 | 0.080 |
Why?
|
| DNA Damage | 3 | 2019 | 90 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2011 | 171 | 0.080 |
Why?
|
| Brain Mapping | 2 | 2009 | 190 | 0.080 |
Why?
|
| Caffeine | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cell Line | 3 | 2018 | 454 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1479 | 0.070 |
Why?
|
| Carcinogens | 2 | 2014 | 36 | 0.070 |
Why?
|
| Myosins | 1 | 2009 | 12 | 0.070 |
Why?
|
| Curriculum | 1 | 2011 | 203 | 0.070 |
Why?
|
| Swimming | 1 | 2009 | 7 | 0.070 |
Why?
|
| Citalopram | 1 | 2009 | 6 | 0.070 |
Why?
|
| Erythrocyte Count | 1 | 2009 | 4 | 0.070 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2009 | 12 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2017 | 1076 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2009 | 22 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2009 | 36 | 0.070 |
Why?
|
| Malocclusion, Angle Class III | 2 | 2018 | 3 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 82 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 258 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 3 | 2013 | 65 | 0.070 |
Why?
|
| Comorbidity | 3 | 2016 | 565 | 0.070 |
Why?
|
| Nursing Homes | 2 | 2005 | 33 | 0.070 |
Why?
|
| Neurons | 1 | 2012 | 486 | 0.070 |
Why?
|
| Intracranial Thrombosis | 1 | 2008 | 8 | 0.070 |
Why?
|
| Reperfusion | 2 | 2020 | 21 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2010 | 243 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2019 | 200 | 0.070 |
Why?
|
| Pain | 1 | 2010 | 303 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2019 | 565 | 0.070 |
Why?
|
| Work Schedule Tolerance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Equipment Design | 3 | 2017 | 178 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 28 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2007 | 16 | 0.070 |
Why?
|
| Workload | 1 | 2007 | 32 | 0.060 |
Why?
|
| Postal Service | 1 | 2007 | 10 | 0.060 |
Why?
|
| Acute Disease | 2 | 2020 | 253 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2009 | 299 | 0.060 |
Why?
|
| Television | 1 | 2007 | 14 | 0.060 |
Why?
|
| Geography | 1 | 2007 | 30 | 0.060 |
Why?
|
| Biopsy | 3 | 2013 | 252 | 0.060 |
Why?
|
| Sample Size | 1 | 2007 | 38 | 0.060 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.060 |
Why?
|
| Tetracycline | 1 | 2007 | 12 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 26 | 0.060 |
Why?
|
| Demography | 1 | 2007 | 101 | 0.060 |
Why?
|
| Transgenes | 1 | 2007 | 46 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 203 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 106 | 0.060 |
Why?
|
| North Carolina | 2 | 2016 | 1300 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 60 | 0.060 |
Why?
|
| Pruritus | 1 | 2007 | 46 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2007 | 66 | 0.060 |
Why?
|
| General Surgery | 1 | 2007 | 84 | 0.060 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2006 | 1 | 0.060 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 14 | 0.060 |
Why?
|
| Vertebral Artery | 1 | 2006 | 6 | 0.060 |
Why?
|
| Cerebral Veins | 1 | 2006 | 11 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 164 | 0.060 |
Why?
|
| Skull | 1 | 2006 | 45 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 128 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2013 | 471 | 0.060 |
Why?
|
| Phantoms, Imaging | 3 | 2012 | 70 | 0.060 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 338 | 0.060 |
Why?
|
| Neurotic Disorders | 1 | 2005 | 1 | 0.060 |
Why?
|
| Behavioral Symptoms | 1 | 2005 | 3 | 0.060 |
Why?
|
| Jaw, Edentulous, Partially | 1 | 2005 | 1 | 0.060 |
Why?
|
| Bicuspid | 1 | 2005 | 2 | 0.060 |
Why?
|
| Denture, Partial, Fixed | 1 | 2005 | 2 | 0.060 |
Why?
|
| Osmosis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Alveolar Process | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mesenteric Veins | 2 | 2002 | 10 | 0.060 |
Why?
|
| Homes for the Aged | 1 | 2005 | 13 | 0.060 |
Why?
|
| Convection | 1 | 2005 | 8 | 0.060 |
Why?
|
| Splints | 1 | 2005 | 13 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 114 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 42 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 248 | 0.060 |
Why?
|
| Cadaver | 1 | 2005 | 151 | 0.060 |
Why?
|
| Dermatitis, Atopic | 1 | 2007 | 103 | 0.060 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 4 | 0.050 |
Why?
|
| Urinary Calculi | 1 | 2004 | 7 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 26 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2021 | 666 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 256 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2004 | 52 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 179 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 543 | 0.050 |
Why?
|
| Aortography | 1 | 2004 | 16 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 95 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 250 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 1437 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2004 | 84 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 81 | 0.050 |
Why?
|
| Dermatologic Agents | 1 | 2007 | 233 | 0.050 |
Why?
|
| Colonic Pouches | 1 | 2003 | 9 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2003 | 7 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 555 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 33 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 56 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 58 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2003 | 24 | 0.050 |
Why?
|
| Deoxyguanosine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Nitrilotriacetic Acid | 1 | 2002 | 7 | 0.050 |
Why?
|
| Ferric Compounds | 1 | 2002 | 15 | 0.050 |
Why?
|
| Bleomycin | 1 | 2002 | 12 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2002 | 34 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 101 | 0.050 |
Why?
|
| Aorta | 1 | 2003 | 125 | 0.050 |
Why?
|
| Omentum | 1 | 2002 | 25 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 17 | 0.050 |
Why?
|
| Endometrial Hyperplasia | 1 | 2002 | 11 | 0.050 |
Why?
|
| Heart Atria | 1 | 2003 | 81 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 85 | 0.050 |
Why?
|
| Portography | 1 | 2002 | 1 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2002 | 28 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 69 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2005 | 320 | 0.050 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2002 | 17 | 0.050 |
Why?
|
| Portal Vein | 1 | 2002 | 27 | 0.050 |
Why?
|
| Spinal Cord Diseases | 1 | 2002 | 14 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 77 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2004 | 349 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 113 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 19 | 0.040 |
Why?
|
| Sex Factors | 2 | 2013 | 655 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2012 | 37 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 21 | 0.040 |
Why?
|
| Furosemide | 1 | 2020 | 8 | 0.040 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2019 | 1 | 0.040 |
Why?
|
| Diuretics | 1 | 2020 | 28 | 0.040 |
Why?
|
| Enterocytes | 1 | 2019 | 7 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2019 | 22 | 0.040 |
Why?
|
| France | 1 | 2019 | 2 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 97 | 0.040 |
Why?
|
| Liver | 1 | 2002 | 492 | 0.040 |
Why?
|
| Superior Cervical Ganglion | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 25 | 0.040 |
Why?
|
| Ligation | 1 | 2019 | 64 | 0.040 |
Why?
|
| Pupil | 1 | 2019 | 4 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 273 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 63 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 893 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 42 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2002 | 256 | 0.040 |
Why?
|
| Homeostasis | 1 | 2019 | 130 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 98 | 0.040 |
Why?
|
| Energy Intake | 1 | 2019 | 122 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2019 | 135 | 0.040 |
Why?
|
| BALB 3T3 Cells | 1 | 2018 | 1 | 0.040 |
Why?
|
| Jaw | 1 | 2018 | 2 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 113 | 0.040 |
Why?
|
| Lecithins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2012 | 38 | 0.040 |
Why?
|
| DNA Repair | 1 | 2019 | 55 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2012 | 499 | 0.040 |
Why?
|
| Retina | 1 | 2019 | 86 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2019 | 45 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 79 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 70 | 0.040 |
Why?
|
| Longevity | 1 | 2018 | 23 | 0.040 |
Why?
|
| Cells, Immobilized | 1 | 2018 | 22 | 0.040 |
Why?
|
| Radiography, Interventional | 2 | 2013 | 32 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 80 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 979 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 104 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 25 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 961 | 0.030 |
Why?
|
| Fluorescence | 1 | 2017 | 22 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 192 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2017 | 16 | 0.030 |
Why?
|
| Biological Products | 1 | 2019 | 79 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 197 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 23 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 82 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 19 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 556 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 1083 | 0.030 |
Why?
|
| Color | 1 | 2017 | 12 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 24 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 59 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 90 | 0.030 |
Why?
|
| Polysomnography | 1 | 2017 | 39 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 144 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 591 | 0.030 |
Why?
|
| Neck | 1 | 2017 | 32 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 410 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 285 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 105 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 242 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 84 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 56 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 19 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2017 | 139 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2016 | 42 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 179 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 276 | 0.030 |
Why?
|
| Bite Force | 1 | 2015 | 2 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 355 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2011 | 393 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 180 | 0.030 |
Why?
|
| Molybdenum | 1 | 2014 | 2 | 0.030 |
Why?
|
| Toxicity Tests, Chronic | 1 | 2014 | 4 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 24 | 0.030 |
Why?
|
| Appalachian Region | 1 | 2014 | 23 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 73 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2014 | 6 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 110 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 129 | 0.030 |
Why?
|
| Spectroscopy, Mossbauer | 1 | 2014 | 1 | 0.030 |
Why?
|
| Powder Diffraction | 1 | 2014 | 2 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 144 | 0.030 |
Why?
|
| Crystallization | 1 | 2014 | 18 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 79 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 34 | 0.030 |
Why?
|
| Cell Movement | 1 | 2014 | 167 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2005 | 327 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 132 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 73 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 74 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 56 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 6 | 0.030 |
Why?
|
| Device Approval | 1 | 2013 | 6 | 0.030 |
Why?
|
| Fasting | 1 | 2013 | 88 | 0.020 |
Why?
|
| Causality | 1 | 2013 | 37 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 183 | 0.020 |
Why?
|
| Iohexol | 1 | 2013 | 8 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 55 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 204 | 0.020 |
Why?
|
| Dental Pins | 1 | 2013 | 1 | 0.020 |
Why?
|
| Dental Materials | 1 | 2013 | 2 | 0.020 |
Why?
|
| Friction | 1 | 2013 | 5 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 52 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 78 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2012 | 7 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 15 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 33 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 66 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 20 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 33 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2012 | 9 | 0.020 |
Why?
|
| Durapatite | 1 | 2012 | 9 | 0.020 |
Why?
|
| Serotonin | 1 | 2012 | 44 | 0.020 |
Why?
|
| Cell Death | 1 | 2012 | 79 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 75 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 90 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 651 | 0.020 |
Why?
|
| Porosity | 1 | 2012 | 39 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 73 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2011 | 5 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2012 | 101 | 0.020 |
Why?
|
| Torque | 1 | 2012 | 21 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2011 | 10 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2012 | 78 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 126 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 222 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 49 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 299 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 185 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2011 | 73 | 0.020 |
Why?
|
| Uganda | 1 | 2010 | 9 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2010 | 8 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 21 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2011 | 159 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2010 | 7 | 0.020 |
Why?
|
| Nucleotidases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 211 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 186 | 0.020 |
Why?
|
| Tooth Germ | 1 | 2009 | 1 | 0.020 |
Why?
|
| Tooth Replantation | 1 | 2009 | 1 | 0.020 |
Why?
|
| Tooth, Nonvital | 1 | 2009 | 2 | 0.020 |
Why?
|
| Tooth, Deciduous | 1 | 2009 | 3 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2009 | 14 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 18 | 0.020 |
Why?
|
| Saliva | 1 | 2009 | 39 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 43 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 324 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 99 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 14 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 39 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 413 | 0.020 |
Why?
|
| Protein Folding | 1 | 2009 | 31 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 40 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 54 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2009 | 18 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 112 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 110 | 0.020 |
Why?
|
| Needles | 1 | 2009 | 29 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 250 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 47 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 955 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2007 | 39 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2007 | 11 | 0.020 |
Why?
|
| Emollients | 1 | 2007 | 11 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2007 | 47 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 25 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 68 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 238 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 345 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2005 | 37 | 0.010 |
Why?
|
| Guanine | 1 | 2005 | 14 | 0.010 |
Why?
|
| Cytosine | 1 | 2005 | 10 | 0.010 |
Why?
|
| Viscera | 1 | 2005 | 13 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 32 | 0.010 |
Why?
|
| Skin | 1 | 2007 | 212 | 0.010 |
Why?
|
| Inpatients | 1 | 2005 | 83 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 211 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 2004 | 21 | 0.010 |
Why?
|
| Pericardium | 1 | 2005 | 52 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 242 | 0.010 |
Why?
|
| Linear Models | 1 | 2005 | 425 | 0.010 |
Why?
|
| Imidazoline Receptors | 1 | 2003 | 2 | 0.010 |
Why?
|
| Staurosporine | 1 | 2003 | 3 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2003 | 6 | 0.010 |
Why?
|
| Chromones | 1 | 2003 | 6 | 0.010 |
Why?
|
| Receptor, Insulin | 1 | 2003 | 9 | 0.010 |
Why?
|
| Integrin alpha5beta1 | 1 | 2003 | 2 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 33 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 15 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 2003 | 19 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 92 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 177 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 702 | 0.010 |
Why?
|
| Constriction | 1 | 2003 | 14 | 0.010 |
Why?
|
| Paraplegia | 1 | 2003 | 7 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 111 | 0.010 |
Why?
|
| Anal Canal | 1 | 2003 | 34 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 42 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2002 | 25 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 25 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 196 | 0.010 |
Why?
|
| Intubation | 1 | 2002 | 5 | 0.010 |
Why?
|
| Endometrium | 1 | 2002 | 44 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2002 | 23 | 0.010 |
Why?
|
| Myelography | 1 | 2002 | 1 | 0.010 |
Why?
|
| Punctures | 1 | 2002 | 32 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2002 | 22 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2003 | 123 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 2002 | 12 | 0.010 |
Why?
|
| Oxygen | 1 | 2002 | 138 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 2002 | 35 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 274 | 0.010 |
Why?
|
| Ureter | 1 | 2002 | 39 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 863 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 147 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 223 | 0.010 |
Why?
|
| Ischemia | 1 | 2002 | 115 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2002 | 72 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 255 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 623 | 0.010 |
Why?
|
| Obesity | 1 | 2005 | 1111 | 0.010 |
Why?
|